Navigation Links
Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
Date:12/6/2011

ANAHEIM, Calif., Dec. 6, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) announced today that executive management will present at the Oppenheimer Healthcare Conference to be held on December 13-14, 2011 in New York.  Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Tuesday, December 13, 2011 at 2:45 p.m. ET. 

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm.  The replay will be available for 90 days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product, Acthar, helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
2. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
3. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
4. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
9. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
10. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
11. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... announced its GHS Label Guide . To align chemical container labeling with ... guide includes explanations of label components, an example of an accurate label, and ...
(Date:7/29/2015)... ... 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers FDA ... combinations. The current system received a score of 0 (range -10 to +10) for ... of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. ...
(Date:7/29/2015)... SAINT-MALO, FRANCE (PRWEB) , ... July 29, 2015 ... ... , Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel, a nighttime-specific product ... limits the amount of sugars that are able to enter fat cells, inhibiting ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Brady Announces a New GHS Label Guide 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3
... India have demonstrated that producing nanoscopic crystals of a pharmaceutical ... gut even if the drug is not soluble in water. ... drugs being developed by the pharmaceutical industry dissolve only very ... problem for administering such drugs as it means they are ...
... InterMune, Inc. (Nasdaq: ITMN ) today ... rights to danoprevir (also known as RG7227 or ITMN-191) ... for $175 million in cash.  In connection with this ... into in October 2006 has been terminated.  In addition, ...
... SEATTLE, Oct. 6 Glencoe Software, Inc., The ... University Press are pleased to announce the release of ... first scientific image data publication system. First released in ... been under continuous development to support new image data ...
Cached Biology Technology:Nano drugs 2InterMune Sells Danoprevir Rights to Roche for $175 Million 2InterMune Sells Danoprevir Rights to Roche for $175 Million 3InterMune Sells Danoprevir Rights to Roche for $175 Million 4Glencoe Software and The Journal of Cell Biology Pioneer Online Publishing of Scientific Image Data: New Version of JCB DataViewer Released 2Glencoe Software and The Journal of Cell Biology Pioneer Online Publishing of Scientific Image Data: New Version of JCB DataViewer Released 3
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... Honey is the original sweetener, manufactured by honey ... cave paintings depict honey gatherers, as do ancient Egyptian ... been important to nearly every human culture and cuisine. ... chemistry, its history, its unbelievable activity. It,s just an ...
... as environmentally conscious stand-ins for such chemicals as ... air-conditioning systems found in many large buildings. But ... suggests that this diverse class of water-treatment devices ... to flourish in the cooling systems of hospitals, ...
... lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates ... cancers, according to data presented at the 33rd Annual ... Full results were presented at the symposium during a ... CT. Reporters who cannot attend in person ...
Cached Biology News:2 books explore the history and delights of honey, bees and beehives 22 books explore the history and delights of honey, bees and beehives 32 books explore the history and delights of honey, bees and beehives 4Pitt study finds 'green' water treatments may not kill bacteria in large building cooling systems 2Combination therapy reduced HER2-positive breast cancers 2
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... years of expertise in the field of ... the most powerful systems on the market. ... 000 in-microplate tests requiring incubation and washing ... modules (such as worktable shaker incubators, reader,washer), ...
... Microsphere/Microarray Stabilizer is a is a bovine ... This product is an aqueous solution that ... (phosphate buffered saline), pH 6.6 - 7.2. ... 0.02% methylisothiazolone and 0.02% bromonitrodioxane as a ...
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
Biology Products: